Sotorasib versus docetaxel for previously treated KRAS G12C-mutated non-small-cell lung cancer: a plain language summary.
- DOI
- 10.1080/14796694.2025.2474789
- Published
- 2025-03-24
- Container
- Future Oncol
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1080/14796694.2025.2474789,
title = {Sotorasib versus docetaxel for previously treated KRAS G12C-mutated non-small-cell lung cancer: a plain language summary.},
author = {de Langen AJ and Johnson ML and Mazieres J and Dingemans AC and Mountzios G and Pless M and Wolf J and Schuler M and Lena H and Skoulidis F and Yoneshima Y and Kim SW and Linardou H and Novello S and van der Wekken AJ and Chen Y and Peters S and Felip E and Solomon BJ and Ramalingam SS and Dooms C and Lindsay CR and Ferreira CG and Blais N and Obiozor CC and Wang Y and Mehta B and Varrieur T and Ngarmchamnanrith G and Stollenwerk B and Waterhouse D and Paz-Ares L and CodeBreaK 200 Investigators.},
year = {2025},
journal = {Future Oncol},
doi = {10.1080/14796694.2025.2474789},
url = {https://doi.org/10.1080/14796694.2025.2474789}
}RIS
TY - JOUR TI - Sotorasib versus docetaxel for previously treated KRAS G12C-mutated non-small-cell lung cancer: a plain language summary. AU - de Langen AJ AU - Johnson ML AU - Mazieres J AU - Dingemans AC AU - Mountzios G AU - Pless M AU - Wolf J AU - Schuler M AU - Lena H AU - Skoulidis F AU - Yoneshima Y AU - Kim SW AU - Linardou H AU - Novello S AU - van der Wekken AJ AU - Chen Y AU - Peters S AU - Felip E AU - Solomon BJ AU - Ramalingam SS AU - Dooms C AU - Lindsay CR AU - Ferreira CG AU - Blais N AU - Obiozor CC AU - Wang Y AU - Mehta B AU - Varrieur T AU - Ngarmchamnanrith G AU - Stollenwerk B AU - Waterhouse D AU - Paz-Ares L AU - CodeBreaK 200 Investigators. PY - 2025 JO - Future Oncol DO - 10.1080/14796694.2025.2474789 UR - https://doi.org/10.1080/14796694.2025.2474789 ER -
APA
AJ, D. L., ML, J., J, M., AC, D., G, M., M, P., J, W., M, S., H, L., F, S., Y, Y., SW, K., H, L., S, N., AJ, V. D. W., Y, C., S, P., E, F., BJ, S., SS, R., C, D., CR, L., CG, F., N, B., CC, O., Y, W., B, M., T, V., G, N., B, S., D, W., L, P., & Investigators., C. 2. (2025). Sotorasib versus docetaxel for previously treated KRAS G12C-mutated non-small-cell lung cancer: a plain language summary.. Future Oncol. https://doi.org/10.1080/14796694.2025.2474789
Source records
- europe-pmc · retrieved 2026-09-27T05:04:23.819Z